PHILADELPHIA, April 27, 2021 – The Â鶹ֱ²¥app (ACP) today released a new with recommendations for the appropriate use of high-flow nasal oxygen in hospitalized patients for initial or post-extubation management of acute respiratory failure. The new, evidence-based clinical guideline was published in Annals of Internal Medicine.
Appropriate Use of High-Flow Nasal Oxygen in Hospitalized Patients for Initial or Post-Extubation Management of Acute Respiratory Failure: A Clinical Guideline from the Â鶹ֱ²¥app, is based on the best available evidence on the benefits and harms of high-flow nasal oxygen, taken in the context of costs and patient values and preferences. The target patient population is adult patients with acute respiratory failure treated in a hospital setting (including emergency departments, hospital wards, intermediate/step-down units, and intensive care units). The guideline also includes input from 2 CGC public members and a 7-member CGC Public Panel, who provide layperson perspectives on values and preferences.
High-flow nasal oxygen (HFNO) therapy is a relatively new type of noninvasive respiratory support that has been gaining widespread use for hospitalized patients in recent years. It involves the delivery of warm and humidified oxygen at a flow higher than the patient’s inspiratory flow via a small nasal cannula. The purported benefits of HFNO compared to conventional oxygen therapy (COT) and high-flow systems and noninvasive ventilation (NIV) include improved patient comfort, compliance and physiological advantages, and can be used as respiratory support in critically ill patients for a number of indications including respiratory failure or support post-extubation.
For the management of acute hypoxemic respiratory failure in hospitalized adults, ACP suggests clinicians use high-flow nasal oxygen rather than noninvasive ventilation (NIV). The evidence showed demonstrable improvement in clinically meaningful outcomes, including a large reduction in mortality, modest reduction in intubations and in hospital-acquired pneumonia as well as an improvement in patient comfort. Additionally, the CGC considered that most patients can use HFNO and there are usually no contraindications unless related to issues with fitting the nasal cannula.
In hospitalized adults with post-extubation acute hypoxemic respiratory failure, ACP suggests clinicians use high-flow nasal oxygen rather than conventional oxygen therapy (COT). In this population, evidence showed HFNO may reduce re-intubation slightly and may improve patient comfort compared to COT, and that HFNO may not perform worse than COT with regard to all-cause mortality, hospital-acquired pneumonia, and length of ICU stay
The guideline notes that more research is needed to identify which patients are most likely to benefit from HFNO, particularly by type of acute respiratory failure as evidence was insufficient on patients with hypercapnia.
None of the included studies compared the use of HFNO with NIV or COT for acute respiratory failure in the setting of post lung transplantation, pulmonary embolism, pulmonary arterial hypertension, or asthma. COVID-19 and related treatments were not part of this guideline.
***
About the Â鶹ֱ²¥app
The Â鶹ֱ²¥app is the largest medical specialty organization in the United States with members in more than 145 countries worldwide. ACP membership includes 163,000 internal medicine physicians (internists), related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness. Follow ACP on , and .
ACP Media Contact: Andrew Hachadorian, (215) 351-2514, AHachadorian@acponline.org